OGN
HealthcareOrganon & Co. · Drug Manufacturers - General · $4B
What is Organon & Co.?
Organon & Co. is a healthcare company spun off in 2021 to focus on women's health, biosimilars, and a broad portfolio of established prescription medicines sold globally.
Organon generates revenue by selling prescription therapies across three segments: women's health products such as contraceptives and fertility treatments, biosimilar versions of immunology and oncology biologics, and a large catalog of established brands covering cardiovascular, respiratory, dermatology, and pain management conditions. Products reach patients through drug wholesalers, hospitals, and managed care providers worldwide.
Organon was established in 2021 and is headquartered in Jersey City, US.
- Women's health — contraception and fertility brands including Nexplanon
- Biosimilars — immunology products Brenzys, Renflexis, and Hadlima
- Established cardiovascular brands including Zetia and Cozaar
- Respiratory and dermatology treatments under Singulair, Nasonex, and Elocon
Is OGN a Good Stock to Buy?
UQS Score rates OGN as Below Average overall.
Organon's Quality pillar stands out relative to its other scores, reflecting some operational stability within its diversified product base. Valuation is rated Attractive, suggesting the market may be pricing in significant headwinds.
The Moat, Growth, and Risk pillars all register as Weak, pointing to competitive pressure on established brands and meaningful balance-sheet concerns.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OGN pay dividends?
Yes — Organon & Co. pays a dividend.
Organon pays a regular dividend, which may appeal to income-focused investors. Given the company's large portfolio of mature, cash-generating brands, returning capital to shareholders has been part of its financial strategy since its 2021 spinoff.
When does OGN report earnings?
Organon reports earnings on a quarterly cadence, typical for US-listed equities.
Results have reflected the dual challenge of managing declining legacy brands while growing the biosimilars segment. Revenue trends across segments vary, with women's health providing relative stability.
For the most recent quarter's results, visit Organon's investor relations page directly.
OGN Price History
-69.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Organon & Co.?
Based on Organon & Co.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Organon & Co. do?
Organon develops and sells prescription healthcare products across three areas: women's health, biosimilars, and established branded medicines. Its portfolio spans contraceptives, fertility treatments, biosimilar biologics, and therapies for cardiovascular, respiratory, and dermatological conditions sold in the US and internationally.
Does OGN pay dividends?
Yes, Organon pays a regular dividend. The company's mature brand portfolio generates cash flow that supports shareholder distributions. Investors should check Organon's investor relations page for the current dividend rate and payment schedule.
When does OGN report earnings?
Organon follows a standard quarterly earnings cadence. Specific upcoming report dates are not covered by our data source, so check Organon's investor relations page or a financial calendar for confirmed dates.
Is OGN a good stock to buy?
UQS Score rates OGN as Below Average. While Valuation appears Attractive and Quality is rated Good, the Moat, Growth, and Risk pillars are all Weak. Investors should weigh these factors carefully. The full pillar breakdown is available to Pro members.
Is OGN overvalued?
The UQS Valuation pillar for OGN is rated Attractive, suggesting the stock is not considered expensive relative to its fundamentals at current levels. However, an attractive valuation does not eliminate the risks flagged in other pillars.
What is OGN's market cap bracket?
Organon & Co. is classified as a mid-cap company. This places it in a range that can offer more growth potential than mega-caps but with greater volatility than the largest healthcare conglomerates.
Is OGN a long-term quality investment?
From a long-term quality perspective, OGN's Below Average UQS Score reflects meaningful challenges. Weak Moat and Growth scores suggest limited competitive insulation and modest expansion prospects. The Attractive Valuation may compensate partially, but long-term quality indicators remain mixed.
What sector does OGN belong to?
Organon operates in the Healthcare sector, specifically within specialty pharmaceuticals and biosimilars. Its focus on women's health and established branded medicines positions it in a distinct niche compared with pure-play biotech or large diversified pharma companies.
Unlock Full OGN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics and trend data
- ✓Compare OGN against sector peers on a standardized scoring framework
- ✓Get the full analyst-style view available to Pro members
Pro Analysis
OGN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 42.0 | 61.6 | 21.0 | 22.8 | 15.6 | 96.2 | +0.1 |
| May 19, 2026 | 41.9 | 61.6 | 21.0 | 22.8 | 15.6 | 95.8 | -8.2 |
| May 11, 2026 | 50.1 | 74.8 | 21.0 | 22.8 | 43.8 | 100.0 | +8.3 |
| May 7, 2026 | 41.8 | 61.3 | 21.0 | 22.8 | 14.3 | 96.7 | 0.0 |
| May 4, 2026 | 41.8 | 61.3 | 21.0 | 22.8 | 14.3 | 96.6 | 0.0 |
| Apr 28, 2026 | 41.8 | 61.3 | 21.0 | 23.1 | 14.3 | 96.6 | -0.2 |
| Apr 19, 2026 | 42.0 | 61.3 | 21.0 | 23.8 | 14.3 | 96.6 | 0.0 |
| Apr 18, 2026 | 42.0 | 61.3 | 21.0 | 23.8 | 14.3 | 96.7 | -0.5 |
| Apr 12, 2026 | 42.5 | 61.3 | 21.0 | 23.8 | 14.3 | 100.0 | 0.0 |
| Apr 2, 2026 | 42.5 | 61.3 | 21.0 | 23.7 | 14.3 | 100.0 | — |
OGN — Pillar Breakdown
Quality
— 61.6/100 (25%)Organon & Co. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 22.8/100 (20%)Organon & Co. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 15.6/100 (15%)Organon & Co. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 95.8/100 (15%)Organon & Co. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 21/100 (25%)Organon & Co. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OGN.
Score Composition
Financial Data
More Stock Analysis
How is the OGN UQS Score Calculated?
The UQS (Unified Quality Score) for Organon & Co. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Organon & Co.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Organon & Co. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.